Background: Predicting outcome of breast cancer (BC) patients based on sentinel lymph node (SLN) status without axillary lymph node dissection (ALND) is an area of uncertainty. It influences the decision-making for regional nodal irradiation (RNI). The aim of the NORA (NOdal RAdiotherapy) survey was to examine the patterns of RNI.
introduction Predicting breast cancer (BC) outcome based on sentinel lymph node (SLN) status without axillary lymph node dissection (ALND) is a new area of uncertainty for regional nodal irradiation (RNI) in the adjuvant setting or after primary systemic therapy (PST).
The updated clinical practice guidelines report from the American Society of Clinical Oncology [1] concluded that for patients with early-stage BC with negative SLN and those with 1-2 metastatic SLN receiving whole breast irradiation (WBI) should not undergo ALND. Conversely, women with SLN metastases who will undergo total mastectomy (TM) should be offered ALND. These recommendations are mainly based on two randomized trials [2, 3] . However, several concerns remain about these trials including the short follow-up and the uncertain coverage of the axilla by the tangential fields (TgF) used with three-dimensional conformal radiotherapy (3D-CRT) [4] . In addition, (i) the risk of non-SLN involvement in the axilla depends on the size of SLN metastasis, (ii) locoregional disease control is important for survival and quality of life, (iii) RNI increases disease-free and overall survival [5] [6] [7] and (iv) axillary lymph node radiotherapy (ALN-RT) can allow equivalent regional control to ALND in SLN-positive patients [8] .
Having appreciated the importance of RNI in the era of modern radiotherapy and axillary surgery, some national groups have published guidelines with particular attention to RNI [9, 10] . However, these guidelines are not widely implemented nationally and decision-making still depends mainly on local policy.
The NORA (NOdal RAdiotherapy) survey was designed to examine the patterns of RNI practice in European Organization for Research and Treatment of Cancer (EORTC) affiliated centers according to different clinical scenarios observed after SLNB followed or not by ALND in patients undergoing breastconserving surgery (BCS) or TM with or without PST. The results may help to provide a basis for designing future trials in areas of equipoise in clinical decision-making concerning RNI.
methods
NORA survey was designed to examine the contemporary practice of RNI in EORTC centers. The web-questionnaire was distributed to 88 EORTC centers. Responses from representative of the affiliated centers were registered between July 2013 and January 2014.
The questionnaire included four sections. The first section was dedicated to the BC-related workload, local radiotherapy indications and planning protocols. The rest of the questionnaire has focused on RNI indications after BCS or TM with or without PST. In each of the scenarios, questions were addressed regarding SLNB either followed or not by ALND, and included all nodal involvement status, from tumor cells to ≥10N+. For each situation, internal mammary chain (IMC-RT), supra/infraclavicular (SCN-RT) and ALN-RT indications were questioned.
results institutions and local policy for radiotherapy practice
The distribution of centers, the number of patients treated per month, the use of multidisciplinary meetings and radiotherapy technique validation are presented in Table 1 .
RNI after BCS
When IMC-RT is indicated (for N-, central/inner tumors, for example), only 14 (17%) centers reported to systematically indicate additional SCN-RT. Only half of the centers advocated SCN-RT for intermediate risk patients (1-3N+) . For macrometastatic SLN involvement in patients without ALND, 13 (5%), 55 (65%) and 48 (57%) centers recommended RNI involving IMC, SCN and ALN, respectively (Table 2) .
Regarding the radiotherapy technique used for axillary coverage, 21 (25%) centers responded that TgF are sufficient to cover residual axillary disease in patients with positive SLNs without ALND.
RNI post-mastectomy
In post-mastectomy radiotherapy (PMRT), adverse standard pathological prognostic factors did not impact volume definition for RNI. SCN-RT was recommended as a standard of care for patients with pN0(i+), pN(mi) and pN1 disease in 5 (6%), 53 (63%) and 51 (61%), respectively. Extra-capsular extension (ECE) is considered as the main factor for ALN-RT indication. Furthermore, 34 (40%) centers prescribe ALN-RT in patients with ≥3-4 positive LNs after ALND, irrespective of the number of examined axillary LNs (Table 2) .
RNI after PST
Out of 84 centers, 68 (81%) use pre-PST imaging±biopsy for staging and 63 (75%) declared that the pre-PST nodal status dictates volumes definition for RNI. In patients with ypN0, 67 (80%) centers do not routinely prescribe RNI. Nodal volume definition take into account the final pathological fibrotic changes observed in the axillary LNs in 49 (58%) centers. In ypN0 patients with inner and centrally located tumors, 32 (39%) centers treat the SCN area either alone or including IMC in 23 (27%) centers (Table 3 ).
Nodal irradiation in elderly patients
Out of 84 centers, 82 (98%) reported that RNI is not particularly omitted in patients >70 years of age. Seventy-five centers (90%) responded that they had no fixed upper age limit for RNI.
discussion
The term, RNI, is not uniformly defined in the literature. In historic series, RNI was used to describe large nodal irradiation. After surgery including ALND, ALN-RT and IMC-RT indications have declined over time, because of the low benefit/risk ratio for arm lymphedema and increased risk of vascular and cardiac morbidity/mortality. On the other hand, it is widely recognized that advances in radiotherapy techniques, and systematic multidisciplinary validation of indications have contributed to a marked decrease in late toxicity [11] . In the NORA survey, 80 (95%) centers stated that radiotherapy indications are confirmed at a multidisciplinary meeting and 69 (82%) routinely validate volumes and technique in a dedicated meeting. However, nodal areas are delineated in only 51 (61%) centers. LNs area delineation is particularly important for evaluation of nodal coverage when the complete axillary status is unknown [4] . Before the advent of 3D-CRT, the evaluation of the dose distribution of RNI was impossible. These considerations also apply for recent studies that provide new evidence of the survival benefit of RNI [5] [6] [7] .
RNI by site
In contrast to PMRT [12] , the benefit from separate irradiation of the different nodal areas has never been investigated in a randomized trial after BCS. Thus, it is difficult to quantify the contribution to improved outcome achieved by radiotherapy of the distinct sites. Table 4 summarizes an overview of RNI published data, guidelines and NORA survey results. supraclavicular node radiotherapy RNI indications and volumes are generally based on clinicopathological factors [10] . Yu et al. [13] reported a close relationship between 5-year SCN failure and reduced overall survival in 448 pN1 patients without radiotherapy. Also, ECE was one of the main independent risk factors. When considering only patients with 1-3N+, SCN recurrence has a deleterious impact on outcome with 
SLN, sentinel lymph node (biopsy); ALND, axillary lymph node dissection; RT, radiotherapy; SCN-RT, supraclavicular radiotherapy; IMC-RT, internal mammary chain radiotherapy; ALN-RT, axillary lymph node radiotherapy; pN: pathologic nodal status. only 18% of survival at 10 years [14] . In the NORA survey, 55 (65%) centers indicate at SCN-RT in the case of nodal macrometastatic disease irrespective of SLN or ALND. This rate was lower (34%) in the case of micrometastatic SLN involvement without ALND (Table 2 ). In Canada, the use of SCN-RT in patients with 1-3N+ increased from 23% prior 1997 to 57% thereafter [15] . This was probably due to: (i) the publication of the late results of the PMRT trial that showed a benefit of PMRT including comprehensive RNI for pN1 patients [16] and (ii) the improved 10-year locoregional control by RNI in a large retrospective analysis of 2768 pN1 from the British Columbia database [15] . In terms of recommendations, while the early German (S3 and AGO) [17] guidelines were more restrictive with regard to SCN-RT indications, others such as the French [10] , the US-NCCN and the recent German Society of Radiation Oncology (DEGRO) guidelines do recommend systematic SCN-RT for patients with 1-3N+ [1, 8, 10] . However, these guidelines cannot distinguish the contribution of SCN-RT from the potential effect of IMC-RT on outcome. They are mainly based on the balance between high risk of SCN recurrence and the fear toxicity of IMC-RT. This benefit/risk ratio has advocated the wide use of SCN-RT without IMC-RT in North America [18] . The NORA survey showed that a very low rate of centers (17%) systematically link SCN-RT indication to IMC-RT.
internal mammary chain radiotherapy
It is important to distinguish BCS and PMRT studies for IMC-RT indications. IMC-RT was part of the treatment in most PMRT studies [16, 19] and the two major randomized trials investigating RNI [5, 6] . Only the French randomized trial has specifically addressed the question of IMC-RT contribution as part of PMRT [12] . This trial included 1334 patients who had chest wall and SCN-RT and were randomized to receive or not IMC-RT. The authors conceded that the study might have been underpowered to prove any significant survival benefit for IMC-RT. They admitted that their data do not permit a definite conclusion [12] . These results are in contrast to the large French cohort study on 1630 patients, which showed a significant survival benefit at 10 (+12%) and 20 years (+24%) of IMC-RT in patients with medial/central tumors [20] .
In the European EORTC 22922-10925 study, the question of IMC-RT was addressed in 4004 patients among whom 23% had PMRT. They concluded that IMC-RT should be recommended for patients with involved axillary LNs and/or medially located tumors. Further, in the MA20 trial, RNI, defined as target volume including axilla levels I-III, SCN and IMC nodes, increased locoregional control and survival without distant metastases [6] .
In terms of guidelines, the NCCN [1] states that IMC-RT should be 'strongly considered' for pN1 patients, regardless of the number of affected nodes and irrespective of type of surgery and even for pN0 patients with tumors ≥5 cm after TM. The French guideline recommends, 'SCN and IMC nodes should be systematically irradiated in patients with internal-central tumors and pN1' [10] . The NORA survey showed that centers consider IMC-RT indications differently from the other nodal areas in the case of macrometastatic SLN involvement without ALND. Only 13 (15%) centers recommend IMC-RT, while 55 (65%) and 48 (57%) centers indicated SCN-RT and ALN-RT, respectively. It should be noted that the survey was conducted before the results of the analysis of the EORTC 22922-10925 trial were known [5] .
axillary lymph node radiotherapy
The other controversy concerns axillary irradiation indications in the SLNB era [21] . It has been shown in randomized trials that SCN-RT plus ALN-RT, which are systematically linked as one RT volume, is as effective and less toxic than ALND alone [8] . Thus, with the widespread introduction of the SLNB procedure for staging and the consequently decreased use of ALND, the latter procedure may be increasingly replaced by ALN-RT.
In the NORA survey, 48 (57%) and 55 (65%) of centers indicate, respectively, SCN-RT and ALN-RT in cases of macrometastatic SLN involvement without ALND. In patients with ≥3-4N+, 40% of the centers prescribe ALN-RT irrespective of the number of examined axillary LNs with a significant impact of ECE status on volume definition.
In the French consensus statement, only patients 'with massive involvement after ALND and those who have no ALND' should undergo axillary radiotherapy [10] . Recently, the DEGRO panel stated, 'data do not permit ultimate conclusions whether any local treatment of the axilla can be safely omitted in selected patients with 1-2 involved LNs or in case of micrometastases'. In cases of macroscopic SLN metastases, they concluded that ALN-RT (as part of RNI) should be discussed as an alternative to ALND [9] . The German recommendations are mainly based on the AMAROS trial results showing that ALN-RT and ALND provided both excellent and comparable locoregional control and survival at 5 years with, however, significantly increased incidence of arm lymphedema in the latter [8] . However, the design and the results of the AMAROS may raise discussion regarding: (i) the potential 'overtreatment' using extensive RNI including axilla levels, (ii) the imbalance in the distribution of SNL-positive patients in the two arms, (iii) the 5-year axillary recurrence rate which was far below that hypothesized and (iv) the short follow-up which could not result in enough axillary recurrences for sufficient statistical power and better evaluation of late cardiac toxicity. When ALN-RT is indicated, the debate concerns the technique and dose optimization. The excellent outcome observed in the ACOSOG-Z0011 trial was attributed to the coincident dose to the axilla delivered by the TgF used to treat the breast volume [2] . Radiotherapy nodal volumes details were available from the report forms of only 605 patients. The radiotherapy charts could be reviewed in only 288 patients. No clear conclusion could be drawn from the analysis on whether additional RNI was necessary or beneficial for these patients [22] .
A compromise accounting for a potentially increased risk of locoregional recurrence of SLN-positive patients was proposed by Henri Mondor team. Their approach to use 'high TgF' or 'direct fields' to cure potential axillary residual disease was supported by the limited coverage of axillary contents including the SLNB area when only standard TgF are planned to treat the axilla [4, 21] . In the NORA survey, only 21 (25%) centers declared that TgF cover residual axillary disease adequately in SLN-positive patients without ALND.
RNI by site after PST and surgery
PST is the accepted approach for women with locally advanced BC for whom immediate surgery is not feasible. Usually, an ultrasound-guided fine needle aspiration of suspicious nodes is carried out before PST to determine axillary nodal status. The NORA survey showed that 68 (81%) centers use pre-PST imaging and/or biopsy for staging.
The indications for adjuvant radiotherapy in patients who underwent PST are generally based on similar prognostic factors as those used to indicate radiotherapy following primary BCS or TM [10] . Therefore, the pre-PST disease criteria are important as they often dictate the RNI volumes. In NORA survey, 63 [23] .
In cases of ypN1, there were predictably a higher number of centers that indicate RNI by site according to the degree of involvement. SCN-RT is delivered by 36-80% of the centers in patients with ypN(i+) to >3-4N+ disease. Axillary volume alone is irradiated in 25% and 40% of the centers in patients with ypN (mi) or 1-2N+ and >3-4N+ disease, respectively. These differences between centers probably reflect uncertainties among radiation oncologists on the indications for RNI and appropriate volumes in the adjuvant setting. The ongoing phase III ALLIANCE trial has been designed in patients with cT1-3N1 BC to compare ALND with axillary irradiation in patients with residual 1-6 SLN/non-SLN-positive after PST [23] .
RNI in elderly patients
While Oxford overview of BCS trials showed a twofold reduction in first relapse even in 'low risk' older patients, the recent report from the SIOG-task force could not draw any RNI guidelines for BC elderly patients [24] . Indeed, RNI has never been considered as a relevant question for elderly patients. Conversely, when considering breast radiotherapy, the CALGB9343 trial showed in patients aged ≥70 year with tumors ≤2 cm, a superiority of combined WBI+tamoxifen over tamoxifen alone in terms of local control. However, this gain did not translate into an advantage for 10-year survival [25] . In NORA survey, adjuvant RNI indication is neither restricted by an upper age limit (90% of the centers) nor omitted in patients over 70 years (98% of the centers).
conclusion
NORA is the first survey that aimed to evaluate the practice of RNI by site in the contemporary context of SLNB and 3D-CRT. ALN-RT is indicated by 40% of the centers in patients with ≥3-4 positive LNs, irrespective of the number of nodes examined in the ALND. New trials testing RNI in the SLN micro/macrometastases patients are needed.
In the PST setting, the large majority of the centers do not indicate RNI in ypN0 patients. While ALLIANCE trial aims to determine the best nodal management option (ALND versus RNI) in post-PST SLN/non-SLN-positive patients, and NSABP-B51/ RTOG investigate the need of RNI in complete responders, questions on RNI indications by sites and by BC molecular subtypes are pending. Additionally, a trial investigating RNI in ypN0 patients with pre-PST cN0 or Nx status could help to determine the role of radiotherapy in locoregional control and its impact on survival.
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